FindTrial
Sign In

A study on the association between ?-Glutamyl Transpeptidase to Albumin Ratio (GAR) and postoperative adverse outcomes in pediatric congenital heart disease.

A study on the association between ?-Glutamyl Transpeptidase to Albumin Ratio (GAR) and postoperative adverse outcomes in pediatric congenital heart disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100678
Enrollment
Unknown
Registered
2025-04-14
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart disease

Interventions

Favorable prognosis group:None
Aadverse prognosis group:None

Sponsors

Kunming Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Children with CHD who are under 18 years old and have undergone extracorporeal circulation assisted surgery.

Exclusion criteria

Exclusion criteria: Patients without complete GAR (ratio of glutamyltranspeptidase to albumin) test data; Patients without weight and surgical risk score (Rachs-1 surgical risk score for congenital heart disease); Patients who underwent a second surgery were excluded.

Design outcomes

Primary

MeasureTime frame
Gamma-Glutamyl Transferase to Albumin Ratio, GAR;Death;Length of Stay;Mechanical ventilation duration;Reintubation;—

Countries

China

Contacts

Public ContactMinxiao Li

Kunming Children's Hospital

lmx18687403105@163.com+86 186 8740 3105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026